Report of Foreign Issuer (6-k)
06 May 2019 - 9:12PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C.
20549
FORM 6-K
Report of Foreign
Private Issuer Pursuant to Rule 13a-16 or 15d-16
Under the Securities
Exchange Act of 1934
For the Month of
May 2019
001-36203
(Commission File
Number)
CAN-FITE BIOPHARMA
LTD.
(Exact name of Registrant
as specified in its charter)
10 Bareket Street
Kiryat Matalon,
P.O. Box 7537
Petach-Tikva 4951778,
Israel
(Address of principal
executive offices)
Indicate by check
mark whether the registrant files or will file annual reports under cover
Form 20-F or
Form 40-F.
Form 20-F
þ
Form 40-F ☐
Indicate by check
mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T
Rule 101(b)(1): ____
Indicate by check
mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T
Rule 101(b)(7): ____
The first paragraph and “Forward
Looking Statements” of the press release attached to this Form 6-K are hereby incorporated by reference into the registrant’s
Registration Statements on Form S-8 (File No. 333-227753) and Form F-3 (File Nos. 333-195124, 333-204795, 333-209037 and 333-220644),
to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently
filed or furnished.
On May 6, 2019, Can-Fite BioPharma Ltd. issued a press release
announcing it is conducting preparatory work for a planned pivotal Phase III study of its drug candidate Namodenoson in the treatment
of advanced liver cancer in patients as a first line and second line treatment. A copy of this press release is attached hereto as Exhibit
99.1 and is incorporated herein by reference.
Exhibit Index
Exhibit Index
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
Date: May 6, 2019
|
By:
|
/s/
Pnina Fishman
|
|
|
Pnina Fishman
|
|
|
Chief Executive Officer
|
4
Can Fite BioPharma (AMEX:CANF)
Historical Stock Chart
From Apr 2024 to May 2024
Can Fite BioPharma (AMEX:CANF)
Historical Stock Chart
From May 2023 to May 2024